Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Summit Therapeutics (SMMT) over the last 10 years, with Q3 2025 value amounting to $15.3 million.

  • Summit Therapeutics' Non-Current Assets rose 2150.14% to $15.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.9 million, marking a year-over-year increase of 489.53%. This contributed to the annual value of $11.8 million for FY2024, which is 1078.04% down from last year.
  • Latest data reveals that Summit Therapeutics reported Non-Current Assets of $15.3 million as of Q3 2025, which was up 2150.14% from $14.8 million recorded in Q2 2025.
  • Over the past 5 years, Summit Therapeutics' Non-Current Assets peaked at $26.5 million during Q3 2021, and registered a low of $6.9 million during Q1 2023.
  • Moreover, its 5-year median value for Non-Current Assets was $13.5 million (2023), whereas its average is $14.7 million.
  • Per our database at Business Quant, Summit Therapeutics' Non-Current Assets tumbled by 5967.6% in 2023 and then surged by 9673.94% in 2024.
  • Over the past 5 years, Summit Therapeutics' Non-Current Assets (Quarter) stood at $16.1 million in 2021, then plummeted by 53.58% to $7.5 million in 2022, then surged by 77.53% to $13.2 million in 2023, then decreased by 10.78% to $11.8 million in 2024, then rose by 29.24% to $15.3 million in 2025.
  • Its Non-Current Assets stands at $15.3 million for Q3 2025, versus $14.8 million for Q2 2025 and $13.1 million for Q1 2025.